Abstract
The antimicrobial peptide LL-37 is the only cathelicidin that has been described in humans. LL-37 exerts chemotactic, immunomodulatory and angiogenic effects; activities that are mediated through binding to the formyl peptide receptor like (FPRL)-1 receptor. Agonistic ligation of FPRL-1 can also induce down-regulation of HIV-1 chemokine receptors and reduce susceptibility to HIV-1 infection in vitro. Therefore, we have evaluated the capacity of LL-37 to inhibit HIV-1 infection in vitro. Here we demonstrate that LL-37 inhibits HIV-1 replication in PBMC, including primary CD4+ T cells. This inhibition was readily reproduced using various HIV-1 isolates without detectable changes in the target cell expression of HIV-1 chemokine receptors. Accordingly, the HIV-1 inhibitory effect was shown to be independent of FPRL-1 signalling. Given the epithelial expression of LL-37, it may contribute to the local protection against HIV-1 infection.
Keywords: Antimicrobial peptide, cathelicidin, innate immunity, HIV-1, LL-37, FPRL-1
Current HIV Research
Title: The Antimicrobial Peptide LL-37 Inhibits HIV-1 Replication
Volume: 5 Issue: 4
Author(s): Peter Bergman, Lilian Walter-Jallow, Kristina Broliden, Birgitta Agerberth and Johan Soderlund
Affiliation:
Keywords: Antimicrobial peptide, cathelicidin, innate immunity, HIV-1, LL-37, FPRL-1
Abstract: The antimicrobial peptide LL-37 is the only cathelicidin that has been described in humans. LL-37 exerts chemotactic, immunomodulatory and angiogenic effects; activities that are mediated through binding to the formyl peptide receptor like (FPRL)-1 receptor. Agonistic ligation of FPRL-1 can also induce down-regulation of HIV-1 chemokine receptors and reduce susceptibility to HIV-1 infection in vitro. Therefore, we have evaluated the capacity of LL-37 to inhibit HIV-1 infection in vitro. Here we demonstrate that LL-37 inhibits HIV-1 replication in PBMC, including primary CD4+ T cells. This inhibition was readily reproduced using various HIV-1 isolates without detectable changes in the target cell expression of HIV-1 chemokine receptors. Accordingly, the HIV-1 inhibitory effect was shown to be independent of FPRL-1 signalling. Given the epithelial expression of LL-37, it may contribute to the local protection against HIV-1 infection.
Export Options
About this article
Cite this article as:
Peter Bergman , Lilian Walter-Jallow , Kristina Broliden , Birgitta Agerberth and Johan Soderlund , The Antimicrobial Peptide LL-37 Inhibits HIV-1 Replication, Current HIV Research 2007; 5 (4) . https://dx.doi.org/10.2174/157016207781023947
DOI https://dx.doi.org/10.2174/157016207781023947 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
HIV vaccine development
The development of a safe and effective vaccine that impedes HIV-1 transmission and/or limits the severity of infection remains a public health priority. The HIV-1/AIDS pandemic continues to have a disproportionate impact on vulnerable and under-served communities in the USA and globally. In the USA, minority communities that have relatively ...read more
Lymphomas in people living with HIV (PLWH)
In the era of combined antiretroviral therapy (cART), the incidence of lymphoma among people living with HIV (PLWH) surpassed Kaposi's sarcoma in 2011, becoming the most common AIDS-defining malignancy. The annual incidence rate ranges approximately from 100 to 300 per 100,000 individuals with HIV infection as the population denominator, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Developments in the Regulation of Monoamine Oxidase Form and Function: Is the Current Model Restricting Our Understanding of the Breadth of Contribution of Monoamine Oxidase to Brain [dys]Function?
Current Topics in Medicinal Chemistry Immune-non Immune Networks in Intestinal Inflammation
Current Drug Targets Vaginal Birth After Cesarean: How to Counsel Patients Using the Evidence
Current Women`s Health Reviews Solid Lipid Nanoparticles and Nanostructured Lipid Carriers of Celecoxib for Topical Application - Preparation, Characterization and Drug Penetration Through Rat Skin
Current Nanoscience Inhalation Gases or Gaseous Mediators As Neuroprotectants for Cerebral Ischaemia
Current Drug Targets Effects of Propolis and Caffeic Acid Phenethyl Ester (CAPE) on Breast Cancer Cells
Current Pharmacogenomics and Personalized Medicine Interferon: Cellular Executioner or White Knight?
Current Medicinal Chemistry Topical Lipid Based Drug Delivery Systems for Skin Diseases: A Review
Current Drug Therapy Hypersensitivity Reactions to Anticoagulant Drugs
Current Pharmaceutical Design Inhibitors of the Microsomal Prostaglandin E2 Synthase-1 as Alternative to Non Steroidal Anti-Inflammatory Drugs (NSAIDs) – A Critical Review
Current Medicinal Chemistry Inflammatory Basis of Atherosclerosis: Modulation by Sex Hormones
Current Pharmaceutical Design Anabolic Steroid - and Exercise - Induced Cardio-Depressant Cytokines and Myocardial β1 Receptor Expression in CD1 Mice
Current Pharmaceutical Biotechnology Immunization with Peptide-Protein Conjugates: Impact on Benchmarking B-Cell Epitope Prediction for Vaccine Design
Protein & Peptide Letters M1/M2 Macrophages in Diabetic Nephropathy: Nrf2/HO-1 as Therapeutic Targets
Current Pharmaceutical Design Nanoparticle-Based Diagnosis and Therapy
Current Drug Targets Cannabinoids and Psychosis
Current Pharmaceutical Design Epitope-Driven TB Vaccine Development: A Streamlined Approach Using Immuno-Informatics, ELISpot Assays, and HLA Transgenic Mice
Current Molecular Medicine Inflammation in Cardiovascular Disease and Regulation of the Actin Cytoskeleton in Inflammatory Cells: The Actin Cytoskeleton as a Target
Cardiovascular & Hematological Agents in Medicinal Chemistry Therapeutic Trials in Human Transmissible Spongiform Encephalopathies: Recent Advances and Problems to Address
Infectious Disorders - Drug Targets Obstructive Sleep Apnea Syndrome and Upper Airway Inflammation
Recent Patents on Inflammation & Allergy Drug Discovery